These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 14715643)

  • 1. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models.
    den Boer M; Voshol PJ; Kuipers F; Havekes LM; Romijn JA
    Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):644-9. PubMed ID: 14715643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.
    Yki-Järvinen H
    Dig Dis; 2010; 28(1):203-9. PubMed ID: 20460912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?
    Caldwell SH; Ikura Y; Iezzoni JC; Liu Z
    J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S11-9. PubMed ID: 17567458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC; Berk PD
    Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
    Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
    Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk.
    Chan JC; Tong PC; Critchley JA
    Semin Vasc Med; 2002 Feb; 2(1):45-57. PubMed ID: 16222595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of ChREBP in hepatic steatosis and insulin resistance.
    Denechaud PD; Dentin R; Girard J; Postic C
    FEBS Lett; 2008 Jan; 582(1):68-73. PubMed ID: 17716660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Macronutrients, fat mass, fatty acid flux and insulin sensitivity].
    Ziegler O; Quilliot D; Guerci B; Drouin P
    Diabetes Metab; 2001 Apr; 27(2 Pt 2):261-70. PubMed ID: 11452220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental rat models to study the metabolic syndrome.
    Aleixandre de Artiñano A; Miguel Castro M
    Br J Nutr; 2009 Nov; 102(9):1246-53. PubMed ID: 19631025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance and steatosis in humans.
    Capeau J
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):649-57. PubMed ID: 19195626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
    Adiels M; Olofsson SO; Taskinen MR; Borén J
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining high-fat-diet rat models: metabolic and molecular effects of different fat types.
    Buettner R; Parhofer KG; Woenckhaus M; Wrede CE; Kunz-Schughart LA; Schölmerich J; Bollheimer LC
    J Mol Endocrinol; 2006 Jun; 36(3):485-501. PubMed ID: 16720718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance.
    Kabir M; Catalano KJ; Ananthnarayan S; Kim SP; Van Citters GW; Dea MK; Bergman RN
    Am J Physiol Endocrinol Metab; 2005 Feb; 288(2):E454-61. PubMed ID: 15522994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
    Pettinelli P; Obregón AM; Videla LA
    Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome.
    Dekker MJ; Su Q; Baker C; Rutledge AC; Adeli K
    Am J Physiol Endocrinol Metab; 2010 Nov; 299(5):E685-94. PubMed ID: 20823452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity upregulates genes involved in oxidative phosphorylation in livers of diabetic patients.
    Takamura T; Misu H; Matsuzawa-Nagata N; Sakurai M; Ota T; Shimizu A; Kurita S; Takeshita Y; Ando H; Honda M; Kaneko S
    Obesity (Silver Spring); 2008 Dec; 16(12):2601-9. PubMed ID: 18846047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance.
    Roden M
    Nat Clin Pract Endocrinol Metab; 2006 Jun; 2(6):335-48. PubMed ID: 16932311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
    Larter CZ; Chitturi S; Heydet D; Farrell GC
    J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the lipogenic pathway in the development of hepatic steatosis.
    Postic C; Girard J
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):643-8. PubMed ID: 19195625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.